Goodbody Stockbrokers maintains that Galen Holdings continues to represent an "excellent" investment opportunity. The shares will be suspended pending its proposed merger with Ferring Pharmaceuticals, possibly until the end of the year. It is viewed as a mini Elan and the impending merger is expected to catapult the company into a different league relative to other European pharmaceutical groups.